scholarly journals Association of mononucleotide polymorphisms of angiotensinogen gene at promoter region with antihypertensive response to angiotensin receptor blockers in hypertensive Chinese

2019 ◽  
Vol 20 (1) ◽  
pp. 147032031982720 ◽  
Author(s):  
Hong-Tao Gong ◽  
Li-Ying Mu ◽  
Tong Zhang ◽  
Xiu-Ying Xu ◽  
Feng-He Du
Keyword(s):  
Blood Pressure ◽  
Angiotensin Receptor Blockers ◽  
Chinese Patients ◽  
Angiotensinogen Gene ◽  
Pressure Lowering ◽  
Receptor Blockers ◽  
Polymerase Chain ◽  
Antihypertensive Response ◽  
The Relationship ◽  
Single Blind

Introduction: This study aimed to investigate whether mononucleotide polymorphisms of the angiotensinogen gene at promoter were associated with the blood-pressure-lowering response to telmisartan treatment. Materials and methods: After a two-week single-blind placebo run-in period, 148 patients with mild-to-moderate primary hypertension received monotherapy with 80 mg/day of telmisartan and then were followed up for eight weeks. The -6A/G and -20A/C polymorphisms of the angiotensinogen gene at promoter were determined through polymerase chain reaction and restriction fragment length polymorphsim analysis. The relationship between these polymorphisms and changes in blood pressure was observed and evaluated after eight weeks of treatment. Results: There were no significant differences between -6A/G, -20A/C polymorphisms of the angiotensinogen gene and blood pressure reductions after treatment, p>0.05. Conclusion: It is suggested that angiotensinogen-6 A/G and angiotensinogen-20 A/C polymorphisms were not associated with the antihypertensive response to telmisartan treatment in Chinese patients with hypertension.

scholarly journals Blood Pressure Control: Stroke and Stroke Prevention

2005 ◽  
Vol 6 (1_suppl) ◽  
pp. S8-S11
Author(s):  
Hans-Christoph Diener
Keyword(s):  
Blood Pressure ◽  
Stroke Prevention ◽  
Antihypertensive Drugs ◽  
Angiotensin Receptor Blockers ◽  
Antihypertensive Agents ◽  
Pressure Control ◽  
Angiotensin Receptor ◽  
Risk Of Death ◽  
Pressure Lowering ◽  
Receptor Blockers

Hypertension is the most important modifiable risk factor for primary and secondary stroke prevention. All antihypertensive drugs are effective in primary prevention: the risk reduction for stroke is 30—42%. However, not all classes of drugs have the same effects: there is some indication that angiotensin receptor blockers may be superior to other classes of antihypertensive drugs in stroke prevention. Seventy-five percent of patients who present to hospital with acute stroke have elevated blood pressure within the first 24—48 hours. Extremes of systolic blood pressure (SBP) increase the risk of death or dependency. The aim of treatment should be to achieve and maintain the SBP in the range 140—160 mmHg. However, fast and drastic blood pressure lowering can have adverse consequences. The PROGRESS trial of secondary prevention with perindopril + indapamide versus placebo + placebo showed a decrease in numbers of stroke recurrences in patients given both active antihypertensive agents, more impressive for cerebral haemorrhage.There were also indications that active treatment might decrease the development of post-stroke dementia.

scholarly journals Renoprotective Properties of Angiotensin Receptor Blockers beyond Blood Pressure Lowering

2005 ◽  
Vol 16 (12) ◽  
pp. 3631-3641 ◽  
Author(s):  
Yuko Izuhara ◽  
Masaomi Nangaku ◽  
Reiko Inagi ◽  
Naoto Tominaga ◽  
Toru Aizawa ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Angiotensin Receptor Blockers ◽  
Angiotensin Receptor ◽  
Blood Pressure Lowering ◽  
Pressure Lowering ◽  
Receptor Blockers

scholarly journals ACE Gene I/D Polymorphism and Obesity in 1,574 Patients with Type 2 Diabetes Mellitus

2016 ◽  
Vol 2016 ◽  
pp. 1-6 ◽  
Author(s):  
Yan-Hong Pan ◽  
Min Wang ◽  
Yan-Mei Huang ◽  
Ying-Hui Wang ◽  
Yin-Ling Chen ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Blood Pressure ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Chinese Patients ◽  
Ace Gene ◽  
Polymerase Chain ◽  
Relationship Of ◽  
The Relationship

Association between ACE gene I/D polymorphism and the risk of overweight/obesity remains controversial. We investigated the possible relationship between ACE gene I/D polymorphism and obesity in Chinese type 2 diabetes mellitus (T2DM) patients. In this study, obesity was defined as a body mass index (BMI) value ≥ 25 kg/m2and subjects were classified into 4 groups (lean, normal, overweight, and obese). PCR (polymerase chain reaction) was used to detect the ACE gene I/D polymorphism in T2DM patients. Metabolic measurements including blood glucose, lipid profile, and blood pressure were obtained. Frequencies of the ACE genotypes (DD, ID, and II) were not significant among the 4 groups of BMI-defined patients (P=0.679) while ACE II carriers showed higher systolic blood pressure (SBP) and pulse pressure (PP) (allP<0.050). Hyperglycemia, hypertension, and dyslipidemia in these T2DM patients were found to be significantly associated with BMI. In conclusion, the relationship of ACE gene I/D polymorphism with obesity is insignificant in Chinese patients with T2DM. SBP and PP might be higher in the ACE II carriers than in the DD and ID carriers.

Sign in / Sign up

Export Citation Format

Share Document